drugset / Trial / NCT00101621

Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain

NCT00101621 ↗

Phase 2 Terminated 24 enrolled MetaPhore Pharmaceuticals
RandomizedFactorialDouble-blindTreatment

Summary

M40403 was found to be effective in reducing pain in animal models and in clinical studies of subjects who were experiencing pain after dental surgery. The proposed study is designed to investigate the efficacy and safety of M40403 when co-administered with an opioid in subjects with pain due to cancer.

Timeline

Start
2004-08
Primary completion
—
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject IMISOPASEM MANGANESE Small molecule 0.0625 mg/kg —
Subject IMISOPASEM MANGANESE Small molecule 0.125 mg/kg —
Subject IMISOPASEM MANGANESE Small molecule 0.25 mg/kg —

Indications